

Company Overview

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

Our Vision


"Every drug can be made and every disease can be treated" through building the open-access platform with the most comprehensive capabilities and technologies in the global healthcare industry.



Statistics updated as of September 30, 2024

Platform and Services

WuXi AppTec is a full-service provider of open-access capabilities and technology that enable customers worldwide to advance discoveries in the health sciences and deliver treatment to those in need. Our services include:



Maintaining the Highest Global Standards

WuXi AppTec is devoted to safeguarding customers' data and intellectual property. A robust system of corporate governance ensures that information is protected and used in accordance with guidelines laid out by our customers and global privacy and healthcare policies.

WuXi AppTec adheres to global regulatory standards across all our business units, and has received regulatory approvals from agencies in Australia, Canada, China, the European Union, Japan, New Zealand, Switzerland and the United States.

Press Release

- 2024/11/12 WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment
- 2024/10/30 WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year
- 2024/10/28 Despite External Challenges, WuXi AppTec Revenue and Profit Continued to Grow QoQ in the First Three Quarters of 2024; the Third Quarter Revenue Back to RMB 10+ Billion, Up 14.6% YoY Excluding COVID-19 Commercial Projects; Backlog Up 35.2% YoY
- 2024/09/02 WuXi AppTec Maintains AA MSCI ESG Rating for the Fourth Consecutive Year
- 2024/07/29 Despite External Challenges, WuXi AppTec Maintained Stable Operations in First Half of 2024; Revenue and Profit of the Second Quarter Both Steadily Improved QoQ as Expected, with Revenue Up 16.0% QoQ and Adjusted Non-IFRS Net Profit Up 28.5% QoQ
- 2024/07/19 WuXi AppTec Named to the FTSE4Good Index Series for the Second Consecutive Year
- 2024/05/23 WuXi AppTec Breaks Ground on New Site in Singapore to Better Support Global Customers
- 2024/04/29 WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations
- 2024/03/18 WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time
- 2024/02/20 WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma
- 2024/01/08 WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site
- 2023/11/09 WuXi AppTec Named 2023 Global Contract Research, Development and Manufacturing Organization Company of the Year by Frost & Sullivan
- 2023/10/30 WuXi AppTec Continued Solid Growth in the First Three Quarters of 2023 on Top of an Exceptionally Strong Year in 2022, with Profit Growth Continuously Exceeding Revenue Growth
- 2023/07/31 WuXi AppTec Announced Strong Results of the Second Quarter and First Half of 2023, on Top of an Exceptionally Strong Year in 2022
- 2023/04/24 WuXi AppTec Continued Solid Growth in First-Quarter of 2023 On Top of an Exceptionally Strong Year of 2022
- 2023/03/20 WuXi AppTec Reports Record Results in 2022
- 2023/02/16 WuXi AppTec Named “Industry Mover” in S&P Global Sustainability Yearbook 2023
- 2022/12/21 WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index
- 2022/11/30 WuXi AppTec Receives 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan
- 2022/10/26 WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion
- 2022/09/26 WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility

[Read more](#)

Awards & Recognitions

Industry Leadership

- 
- A light gray world map is visible in the background of the Industry Leadership section.
- Global Contract Research, Development and Manufacturing Organization Company of the Year (2022-2024)
 - Ranked among “The Future 50” (2020-2021)
 - 50 Smartest Companies (2019)
 - Company of the Year (2018)
 - Heroes of Chemistry Award (2017)
 - Best Company in an Emerging Market (2014)
-

ESG

- Named to the S&P Global Sustainability Yearbook consecutively in 2023-2024
 - CDP “Environmental Leadership Award” in 2022-2023
 - “Silver” rating by EcoVadis in 2023
-

Notes for Media Reports



WuXi AppTec Logo [Download](#)

English Name: WuXi AppTec



The letters “W”, “X”, “A” and “T” should be capitalized, and there is a blank between “WuXi” and “AppTec”.

Media Contact:

mediainquiries@wuxiapptec.com